Merck Agrees to Buy Silence Therapeutics for $1.3 Billion
Merck KGaA said it is offering $20 per American depositary share in cash for the U.K. biotech, adding an experimental polycythemia vera medicine to its pipeline.
Germany-based Merck KGaA has agreed to acquire U.K. biotech Silence Therapeutics for $1.3 billion, adding an experimental treatment for the rare disease polycythemia vera to its drug pipeline. Merck said Monday it is offering $20 in cash for each American depositary share. The offer is for Nasdaq…